Novo Nordisk's Oral Weight Loss Drug Expands GLP-1 Market as Eli Lilly Competes for Patients

Novo Nordisk released an oral pill alternative to injectable GLP-1 medications for obesity treatment, expanding market access beyond injection-dependent patients. The drug faces direct competition from Eli Lilly's oral weight loss medication as both companies vie for market share in the growing obesity treatment sector. Patient adoption rates and real-world efficacy data will determine which oral formulation gains dominant market position. The shift from injectables to pills removes a significant barrier to treatment adoption for millions of Americans managing weight.